TPIV 110

Drug Profile

TPIV 110

Alternative Names: TPIV110

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mayo Clinic
  • Developer Mayo Clinic; TapImmune
  • Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 14 Mar 2017 Mayo Clinic and TapImmune plan a phase Ib/IIa trial in Breast cancer (ductal carcinoma in situ) in USA upon completion of an amended investigational new drug application by end of 2017 and its acceptance by the US FDA
  • 01 Nov 2016 TapImmune plans to submit an amended IND application to the US FDA for Breast cancer
  • 01 Nov 2016 TapImmune plans a phase II trial for Breast Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top